Hansa Biopharma AB (OSTO:HNSA) Total Stockholders Equity : kr-374.2 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Total Stockholders Equity?

Hansa Biopharma AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr-374.2 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Hansa Biopharma AB's Book Value per Share for the quarter that ended in Mar. 2024 was kr-7.10. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Hansa Biopharma AB's Debt-to-Equity for the quarter that ended in Mar. 2024 was -2.53.

Hansa Biopharma AB Total Stockholders Equity Historical Data

The historical data trend for Hansa Biopharma AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Total Stockholders Equity Chart

Hansa Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

562.82

1,242.12

757.57

602.91

-167.88

Hansa Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															414.67	182.18	-62.21	-167.88	-374.21

Hansa Biopharma AB (OSTO:HNSA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Hansa Biopharma AB's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-374.209	-	0)	/	52.6718
	=	-7.10

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Hansa Biopharma AB's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.54	+	939.582)	/	-374.209
	=	-2.53

Hansa Biopharma AB Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansa Biopharma AB (OSTO:HNSA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

HNSBF:USA 0RC7:UK 24H:Germany

Address

Scheelevagen 22, Lund, SWE, 223 63

Website

https://www.hansabiopharma.com

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines